SANTA CLARA (dpa-AFX) - Agilent Technologies Inc. (A) has received FDA
approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in
identifying patients with Gastric or Gastroesophageal Junction Adenocarcinoma
who may be eligible for treatment with KEYTRUDA, Merck's anti-PD-1 therapy. The
company noted that this marks the sixth cancer type for which PD-L1 IHC 22C3
pharmDx has gained FDA approval.

PD-L1 IHC 22C3 pharmDx was developed by Agilent in partnership with Merck as a
companion diagnostic for KEYTRUDA.

For More Such Health News, visit rttnews.com.



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX